Develops medicines and brain-imaging agents for neurodegenerative diseases, partnering with pharmaceutical companies.
20-F for FY2025, filed Mar 13, 2026Leveraging our dual proprietary technology platforms, SupraAntigen and Morphomer, we have built a comprehensive pipeline of first-in-class…View ↗
At AC Immune, we have a strong track record in discovering highly sensitive and specific imaging agents to detect and quantify pathological…View ↗
Our strategy to date has been to focus on identifying partnerships for our product candidates at an appropriate time as both a way to…View ↗
Pharmaceutical partners pay for rights to product candidates and intellectual property through upfront license fees, development, regulatory or commercial milestone payments, research and clinical service fees, and royalties on licensed-product sales. AC Immune earns service fees as it performs the work, and upfront license fees when rights are transferred.
20-F for FY2025, filed Mar 13, 2026The Company enters into OLCAs which are within the scope of IFRS 15, under which it licenses certain rights to its product candidates and…View ↗
If the license to the Company’s intellectual property is determined to be distinct from the other performance obligations identified in the…View ↗
Milestone paymentsView ↗
The Company has certain arrangements with our collaboration partners that include contracting our employees for research and development…View ↗
CHF 3.6M
20-F for FY2025, filed Mar 13, 2026
CHF 3.6M ↗
Pharmaceutical partners license rights to product candidates and intellectual property; some also contract AC Immune for research and clinical services.
20-F for FY2025, filed Mar 13, 2026Leveraging our dual proprietary technology platforms, SupraAntigen and Morphomer, we have built a comprehensive pipeline of first-in-class…View ↗
The Company enters into OLCAs which are within the scope of IFRS 15, under which it licenses certain rights to its product candidates and…View ↗
The Company has certain arrangements with our collaboration partners that include contracting our employees for research and development…View ↗
Strategic emphasis
The older strategy described diagnostics as a distinct pillar alongside Alzheimer’s drug development and expansion into Parkinson’s and other disorders. The latest frames active immunotherapies and small molecules aimed at intracellular disease processes as core product-development drivers, with partnerships supporting business development.
20-F for FY2022, filed Mar 16, 2023 20-F for FY2025, filed Mar 13, 2026
Competes with Biogen, Eisai, Eli Lilly, Axon Neuroscience, Nuravax, TheraVac, Araclon Biotech, Vaxxinity, Alzinova, Aprinoia, Lantheus, Genentech, Roche, Janssen, UCB, Ventyx, NodThera, Ventus, Zydus, and TauRx
20-F for FY2025, filed Mar 13, 2026Currently, there are two commercially available FDA-approved disease-modifying products for AD, Leqembi (Biogen / Eisai) and Kisunla (Eli…View ↗
Loading...